Stock Analiz

Adma Biologics, Inc. (ADMA) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Adma Biologics’s revenue went from $11M in fiscal 2016 to $510M in fiscal 2025, growth of about 53.7% a year.

Net income in fiscal 2025 was $147M, a net margin of 28.8%; the best year in this period was 2024 with $198M.

Over the twelve months to September 30, 2026, revenue was $519M and net income $182M.

Free cash flow was $28M in fiscal 2025 and positive in 3 of the 10 years shown.

The diluted share count rose 1915% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $11M162017: $23M172018: $17M182019: $29M192020: $42M202021: $81M212022: $154M222023: $258M232024: $426M242025: $510M25$510M
Net income
2016: -$20M162017: -$44M172018: -$66M182019: -$48M192020: -$76M202021: -$72M212022: -$66M222023: -$28M232024: $198M242025: $147M25$147M
Free cash flow
2016: -$18M162017: -$40M172018: -$65M182019: -$80M192020: -$115M202021: -$126M212022: -$73M222023: $4M232024: $110M242025: $28M25$28M
EPS (diluted)
2016: $-1.61162017: $-1.91172018: $-1.45182019: $-0.89192020: $-0.88202021: $-0.51212022: $-0.33222023: $-0.13232024: $0.81242025: $0.6025$0.60

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$519M$510M$426M$258M$154M$81M$42M$29M$17M$23M$11M
Gross profit$356M$293M$220M$89M$35M$1M-$19M-$10M-$25M-$6M$4M
Operating income$241M$191M$139M$22M-$39M-$58M-$65M-$41M-$60M-$39M-$17M
Net income$182M$147M$198M-$28M-$66M-$72M-$76M-$48M-$66M-$44M-$20M
EPS (diluted)$0.77$0.60$0.81$-0.13$-0.33$-0.51$-0.88$-0.89$-1.45$-1.91$-1.61
R&D$14M$5M$2M$3M$4M$4M$6M$2M$4M$6M$8M
Revenue growth—+19.6%+65.1%+67.6%+90.4%+91.7%+43.9%+72.8%−25.4%+113.5%+48.5%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$141M$50M$119M$9M-$60M-$112M-$102M-$76M-$63M-$37M-$18M
Capital spending-$8M-$23M-$8M-$5M-$14M-$14M-$13M-$4M-$2M-$3M-$73410
Free cash flow$133M$28M$110M$4M-$73M-$126M-$115M-$80M-$65M-$40M-$18M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$189M$32M$0$0———————
Stock-based pay$24M$20M$14M$6M$5M$3M$3M$3M$2M$2M$1M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$88M$103M$51M$87M$51M$56M$27M$27M$43M$15M
Debt—$80M$82M$141M$154M$103M$105M$70M$26M$25M$18M
Equity—$477M$349M$135M$152M$141M$88M$26M$20M$40M-$4M
Total assets—$624M$489M$329M$348M$276M$208M$127M$89M$108M$24M
Shares (diluted)226M245M243M224M198M140M86M54M45M23M12M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin68.5%57.4%51.5%34.4%22.9%1.5%-45.2%-34.6%-148.4%-28.1%40.3%
Operating margin46.5%37.5%32.6%8.4%-25.6%-72.1%-153.8%-141.1%-354.9%-172.7%-162.6%
Net margin35.1%28.8%46.4%-10.9%-42.8%-88.5%-179.4%-164.5%-387.1%-192.3%-183.1%
FCF margin25.6%5.5%25.9%1.6%-47.6%-155.5%-271.7%-272.6%-381.4%-175.5%-172.0%
ROIC—27.6%25.5%7.8%-12.8%-18.9%-26.6%-34.1%-103.1%-47.3%-124.0%
ROE—30.8%56.6%-20.9%-43.4%-50.7%-85.8%-184.3%-332.5%-108.5%437.8%

Frequently asked questions

What is Adma Biologics’s annual revenue?

$510M in fiscal 2025 and $519M over the twelve months to September 30, 2026.

How much profit does Adma Biologics make?

Net income was $147M in fiscal 2025 (net margin 28.8%).

Is Adma Biologics’s revenue growing?

Yes: revenue rose 19.6% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.